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Thank you again for submitting your work to Molecular Systems Biology. We have now heard back from the three referees who agreed to evaluate your manuscript. As you will see from the reports below, the referees raise substantial concerns on your work, which, I am afraid to say, preclude its publication.
In general, the reviewers recognized that this work attempts to address an important question, the similarity between hESCs and hiPSCs, and presents a novel proteomic dataset that is potentially relevant to this issue. Nonetheless, all three reviewers, and particularly the last two, felt that that current analysis did not extend far enough to provide a decisive and convincing advance on this issue. The first reviewer was perhaps the most positive, but also indicated clearly that the differentially expressed proteins observed between hESCs and hiPSCs could have important functional consequences, and that this issue deserved additional analysis. Moreover, the reviewers had a series of technical concerns regarding protein FDR and protein quantification from the mass spectrometry data. These concerns seem significant enough to create some doubt regarding both the functional similarity of the hESCs and hiPSCs cells, and the reproducibility of the protein-level quantifications.
Given these concerns, and since two reviewers indicated clearly that they felt that the biological insights that emerged from this work remained rather modest, we feel we have no choice but to return this work with the message that we cannot offer to publish it.
Nevertheless, the reviewers did express interest in the subject matter and your general approach.
Indeed, it does seem that some of their concerns could potentially be addressed with additional experiments and analysis. As such, we would like to indicate that we may be willing to reconsider an expanded work based on this report. Such a work would certainly require substantial additional experiments that, at minimum, provide a more in-depth analysis of the potential functional consequences of the expression differences observed between the fibroblast, hESCs and hiESCs cell lines, in addition to addressing the more specific technical issues raised by the reviewers.
A resubmission would have a new number and receipt date, and we can give no guarantee about its eventual acceptability. However, if you do decide to follow this course then it would be helpful to enclose with your re-submission an account of how the work has been altered in response to the points raised in the present review.
I am sorry that the review of your work did not result in a more favorable outcome on this occasion, but I hope that you will not be discouraged from sending your work Molecular Systems Biology in the future.
Thank you for the opportunity to examine this work.
Yours sincerely, Section Editor Molecular Systems Biology _______________________ Reviewer #1 (Remarks to the Author):
Since their inception, iPSCs and the extent of their pluripotentiality have been brought into question.
Transcriptional and epigenetic interrogations of hiPSCs have also proven inconclusive on whether these cells are equatable to bona fide hESCs. Hence, there is presently an outstanding equivocation in the field on whether hiPSCs and hESCs are similar to one another (reviewed by Loh and Lim, 2010; Cell Stem Cell) .
To this end, Munoz et al. present here an MS-based comparison of the proteomes of hiPSCs versus hESCs. The concept of the study is appropriate and the results presented are valid. The manuscript is appropriate for publication upon: (1) additional analysis of the proteomics results and (2) minor revisions to the text.
There are technical advantages and disadvantages organic to the MS-based approach employed. MSbased analyses have less sensitivity and quantitative resolution as compared to transcriptional analyses (e.g. microarrays, RNA-seq)-one might contend that small (but important) changes in protein level might account for differences between hiPSCs and hESCs, and also that changes in the expression of noncoding RNAs obviously cannot be discerned (as per Ouyang et al., 2010; Cell Stem Cell) . Nevertheless, the salient benefit of the authors' MS-based study is of course that the proteome (not the transcriptome) is studied.
We highlight salient points about the manuscript below-1. A supermajority of proteins is expressed at similar levels between hESCs and hiPSCs. This is good confirmation but is not altogether surprising. hESCs and hiPSCs share many salient characteristics (the transcriptome-based comparisons of hESCs vs. hiPSCs also generally agree that there are substantial similarities between hESCs and hiPSCs). The more primary question in the field is whether there are very slight, albeit important, differences between hESCs and hiPSCs -the question lays in the details. The perceived novelty of this manuscript does not lie in re-determining whether hESCs and hiPSCs are similar, but rather-what are the differences? 2. We found it very interesting that the authors identified 98 proteins with differential expression between hESCs and hiPSCs. (Other studies at the transcriptional level have claimed differing numbers of transcripts whose expression differ between hESCs and hiPSCs, for example, see Guenther et al., 2010; Cell Stem Cell versus Chin et al., 2009; Cell Stem Cell) . This finding that 98 proteins are differentially expressed is quite conspicuous, and should certainly be followed up on, instead of being mentioned in passing (a claim that 1.6% of proteins are differentially expressed is actually very important!). 3. Further analysis of the differentially expressed proteins is required. The authors already concluded by gene ontology analysis that there are no "significant" pathways enriched amongst the differentially expressed proteins, but this is not sufficient. For example... 4. Are any fibroblast proteins that are enriched in the list of proteins preferentially expressed in hiPSCs vs. hESCs? That is-are fibroblast proteins the ones that are being upregulated in hiPSCs vs. hESCs? This possibility is indeed evocative of a romanticized "epigenetic memory" shared between hiPSCs and their historical antecedents (see Kim et al., 2010 ; Nature and related). The authors should look into this (it shouldn't be too hard-the authors have already generated the data, they just need to further the analysis.) 5. Moreover, it also quite conspicuous that the MS-based analysis found prominent pluripotency genes such as Zic3 and Utf1 that were differentially expressed between hiPSCs and hESCs. This should be commented on. 6. We would like to suggest that for important genes that the MS analysis identified were differentially expressed between hiPSCs and hESCs (e.g. Utf1) that these findings could be validated by qPCR and/or Western Blot. 7. The authors claimed that Dpp6 is differentially expressed between hiPSCs and hESCs (based on transcriptional analyses), but their proteome analysis did not find that Dpp6 was amongst the proteins differentially expressed between hiPSCs and hESCs (only Dpp7 was in the list). This is concerning in regards to their experimental design. 8. Dpp6 in itself is pretty important if it is differentially expressed between hiPSCs and hESCs: it is involved in pancreatic cancer and ALS. 9. The authors should see whether their MS-derived proteome of hESCs intersected with previously published proteomics data of ESCs (to add additional authenticity and confidence to their analysis.) 10. We are wondering if there are incongruities between proteome and transcriptome content. It seems like a straightforward thing to check, yet was apparently omitted-the authors just need to present a figure where they overlap their proteome and transcriptome contents and see if there are any significant differences. Do incongruities between proteome and transcriptome contents reflect an inherent weakness in the MS analysis, or rather, does it argue why transcriptome studies are not very useful predictors of proteome constitution? 11. Moreover, the small sample size (only 1 hiPSC and 1 hESC line were analyzed, respectively) is regrettable. Nevertheless, it seems unreasonable for the authors to repeat their study in highthroughput fashion to include additional cell lines, given the manual intensity of the MS technique.
Nevertheless, in sum, Munoz et al.'s report is still concise, timely, and provides useful resources for future study. It will be of interest to the iPS community, especially given the recent furore about the similarities (or lack thereof) between hESCs and hiPSCs. The concept of the manuscript and the results presented are very interesting-nevertheless, this study could be even further strengthened by a more detailed analysis of the data presented, and also a slight redirection in the focus of the paper to also examine more in depth the reportedly differentially expressed proteins between hESCs and hiPSCs.
We believe that the manuscript may be accepted for publication with only minor revisions: namely, (1) accounting for minor grammatical/factual mistakes, as discussed below, (2) further analysis/discussion of differentially expressed proteins in hESCs vs. hiPSCs, and furthermore, (3) a brief consideration of whether their proteomics data presents any evidence for an "epigenetic memory" of hiPSCs' fibroblast origins.
Minor issues follow-1. Introduction: should be revised to-"...hESCs are characterized by two unique properties, the capability to self-renew indefinitely and undergo multi-lineage differentiation" 2. Quoting a pre-implantation ICM origin for hESCs is troublesome, especially given that mESCs are actually derived from the epiblast of the peri-implantation blastocyst (see Nichols and Smith, 2009 ; Cell Stem Cell for a brief treatment of the topic) 3. "Whether these ... hiPSCs can be made indistinguishable from their natural counterparts"; a bit awkward phrase, might be better to rephrase it to say "Whether these ... hiPSCs are indistinguishable..." 4. The claim that hiPSCs have the same faculty as hESCs for multilineage differentiation is incorrect and is antithetical to many reports (for example, see Hu et al., 2010; PNAS) 5. "Several studies have directly compared hESCs and hiPSCs at the ... histone marks ... level"; also a bit awkward, maybe "...at the level of histone modifications" instead? 7. The title ("Human induced pluripotent stem cells and embryonic stem cells exhibit alike proteome signatures") is a bit awkward-especially, in regards to usage of the word "alike" and also "proteome" (it would flow better if it said "proteomic signatures"). 8. The abstract's usage of "protein expression programs", while evocative of Guenther et al. (2010) in Cell Stem Cell, is unusual, given that this phrase has not been widely used before (whereas "gene expression programs" has been used) 9. The abstract's claim that "...reprogramming completely extends to the expression level of the global hiPSCs proteome" seems to be a precocious conclusion (and has a minor grammatical error). This study did not find evidence that hiPSCs and hESCs were indistinguishable (see Table S3 ) and the claim should be toned down. 10. Same applies for the conclusion; the claim that "...protein expression levels in hiPSCs and hESCs are hardly distinguishable" is also premature and is not supported by the presented data (e.g. the 98 proteins reported to be differentially expressed) 11. In the "Results and Discussion" section heading, the latter word is misspelled 12. Figure 2 is really complicated and is not very accessible. One may intuit that deconvolving each axis (e.g. the x-axis) enables one to see the protein changes between hiPSCs and hESCs: but presently, it's really hard to understand.
Reviewer #2 (Remarks to the Author):
In this short report, the authors describe a quantitative proteomics analysis of human induced pluripotent stem cells (PSC), human embryonic stem cells (ESC), and the precursor fibroblasts from which the PSC line was derived, and report their findings. The authors have chosen a topic of significant interest and broad general appeal to the readership of molecular systems biology. The rationale for studying how well PSCs recapitulate ESC pluripotency is clear in the context of their potential application in translational medicine and research.
I did struggle a little bit, however, with the idea that a report such as this could generate a sustained, lasting impact on the field, given the relatively binary outcome. Essentially, the authors compared the proteomes of each cell line against the other, and claim to have found few significant and/or reproducible differences, and so are left to conclude that PSCs and ESCs are biologically indistinguishable. Although the authors do make some noise about the present study "filling an important gap in our understanding of pluripotency", they never really say what this new knowledge is specifically. Is it only that PSCs and ESCs generate similar proteomic profiles? How will this current study "serve as a platform for future investigations which more targeted experimentation might reveal"? I'm certainly willing to be convinced of this -I just felt like some of these sweeping, broad generalizations should either be supplemented with specific examples of the value-added to science as a result of these experiments, or risk sounding like "sweeping, broad generalizations".
For example: in my opinion, while it is anecdotally interesting that PSCs and ESCs have similar proteomic profiles, a much, much more interesting and satisfying experiment would be to induce both cell lines to differentiate into another cell type using identical conditions, and then to assess how well the quantitative proteomes of the resulting new cell types compare with each other. Or to quantitatively profile the differentiation process between the two cell types as they differentiate. Such experiments would surely make for much more convincing statements regarding the relatively (dis-)similarity between PSCs and ESCs in a very defined biological context. I'm not outright advocating for such labor-intensive experiments for the present study, but they would certainly represent more focused biological stories.
In any case, it's clear to me via Figure 1 that the proteomes of PSCs and the fibroblasts from which they were derived are indeed different. But what's less clear is if PSCs and ESCs are truly "different" -not just to a specified degree of statistical significance, but really different. Presumably, the authors' analytical strategy of isotope labeling, separation, LC-MS/MS etc. is prone to some nominal level of imprecision. It would be very helpful for readers to evaluate the PSC/ESC correlation plots in Figure 1 by comparing them with either a PSC/PSC or ESC/ESC correlation plot for reference. It may be that those data are even more robust in comparison, which would cause the authors to rethink their conclusions. The specific experiment is taking, say, PSCs, splitting a culture in half, and labeling half light and the other half heavy, and processing them through to the end.
I have a few specific comments that should be addressed prior to publication:
1. The word "alike" in the title is inappropriate. "similar" is perhaps a better word, although the whole sentence could be better phrased if reformulated altogether.
2. The first sentence of the introduction "...by two unique properties;" should be changed to "...by two unique properties: the ability to...".
3. The "characterization" of PSCs by flow cytometry and injection into nude mice, while thorough, doesn't really add much value to the paper. It might if the authors had chosen protein targets that were either different or similar as a result of their analyses -but similar experiments have previously been performed in the literature as part of the initial characterization of these cells, and so is referenceable.
4. The authors should report a protein FDR in addition to the peptide FDR. This is necessary due to the observation that peptide false positives tend to distribute to mostly random protein matches (non-random due to size biases in different proteins), and that 1% of 568,054 is still a pretty large number. This protein FDR can be calculated from the total number of reverse peptide identifications collapsed to their unique protein identifiers relative to the total number of unique, forward protein identifiers (presumably, 10,608 unique proteins) . Furthermore, the authors should clarify if this 10,608 number is the result of any additional, specific filtering -e.g. requirement of 2 or more peptides, only the intersection of the three separate proteomic experiments, etc. In fact, the authors should supply a Venn diagram depicting the overlap of proteins identified for each of the three experiments as part of their supporting information. The concern here is to guard against overinterpretation of their protein identification numbers.
5. On page 5, the authors indicate that "119,371 peptide triplets (7,625 proteins) were quantified and manually verified". The authors are encouraged to expend a sentence or two on what it means to "manually verify" ~120,000 quantification results. Did human eyeballs actually view at that many extracted ion chromatograms? Stunning! 6. On page 5, the authors state "...since most of our protein ratios showed less than 30% relative standard deviations." This should be changed to state explicitly the mean (and/or median) relative standard deviation (e.g. ...the median relative standard deviation (RSD) for these experiments was 30%). Please include this in the figure legend of Supplementary Figure 5 as well.
7. Same for page 5, "...where more than half of the proteins were found to highly differentially expressed." Please state explicitly what fraction of proteins were found to be differentially expressed by what specific criteria.
8. On page 10, the authors describe surprisingly high ion target values for their experiments (10,000 for CID and 50,000 for ETD). Please supply the maximum allowed ion injection times for these experiments.
9. On page 10, the authors search their data with up to 4 missed cleavages. I rarely find more than one missed cleavage to be believable. Is there a reason that this many missed cleavages were considered? Is a considerable portion of their data represented with more than 1 missed cleavage? It's a minor point, but does stand out as unusual.
Reviewer #3 (Remarks to the Author):
In the submitted paper Munoz and co-authors quantify the proteomes of three different cell types: a hES cell line, a human somatic cell line (IMR90) and an induced pluripotent stem cell line derived from the IMR90 cells. In order to compare the three cell lines side-by-side the authors make use of dimethyl labeling in three isotopic variants, SCX fractionation and analyze the resulting peptide mixtures by LC-MS/MS using both CID and ETD for peptide sequencing.
This manuscript mainly presents two key contributions: 1) The difference in protein abundances between iPS cells and the somatic cell line that they are derived from is really significant. 2) There are very few differences in protein expression levels between the embryonic stem cell line and the iPS cells.
But although this paper is potentially interesting there are a number of shortcomings in the current version that needs to be addressed: -The paper is not very exciting in its current form. I lack some novel biological findings. It is not surprising that the proteome between the iPS cells and the somatic cell line is different, but what does the observed differences mean (in a biological and cellular context)? -What type of proteins are stem cell specific and which proteins are specific to the somatic cells? There must be some interesting biology hidden in the data. -The authors should attempt to do some more advanced bioinformatic analyses to extract biological insight from their dataset. For example, the proteins that are significantly more abundant in the iPS cells are they enriched for known transcriptional targets of Nanog, Sox2 and I also have some questions and concerns about the MS analysis/computational parts of the manuscript:
-The authors need to be more rigorous in their data analysis. They claim that they have identified 10,608 proteins -but looking through the supplementary data it is clear that this is a significant overestimation of the actual number of proteins: First of all, the dataset is only FDR filtered at the peptide level,-this is not acceptable for a proteome analysis. Secondly, in the current protein list more than 40% of proteins are identified by a single peptide (a so-called one hit wonder)! This is significantly higher than for any other large-scale dataset published to date. Thirdly, 30% of proteins are not quantified!? -This is an unacceptable high number of peptide identifications that cannot be quantified. The authors need to address these points and adjust their protein numbers accordingly! Guenther et al., 2010; Cell Stem Cell versus Chin et al., 2009; Cell Stem Cell) . This finding that 98 proteins are differentially expressed is quite conspicuous, and should certainly be followed up on, instead of being mentioned in passing (a claim that 1.6% of proteins are differentially expressed is actually very important!).
We agree with this referee that several indirect evidences pointed out that hiPSCs and hESCs could also share a high degree of similarity at the proteome level. However, we believe that interrogation of proteins, the real molecular effectors of cells, can provide a more accurate view of the underlying mechanisms behind these comparisons (especially considering the established fact in the field that mRNA and proteins do not always correlate so well (Lu et al. Nature 2010)). Accordingly, our analysis represents a conclusive confirmation for many of the previous screenings that were conducted mainly at the transcriptomic/epigenetic level. In addition and motivated by the positive reviews we received, we performed a second proteomic analysis on a second hiPS cell line (and its precursor cell line). We have re-analyzed all the data sets using more robust statistical criteria and confirmed that hiPSCs proteomes closely resemble the bona fide hESC proteome. Nevertheless, in both comparisons, we found a group of proteins differentially expressed between hiPSCs and hESCs (four of them intersected between the two analyses). Both, their identities and potential functional relevance in the context of this study are discussed. In that respect, the current idea in the field that a transcriptional/epigenetic memory from the donor cells might be present in the reprogrammed hiPSCs is also discussed with special attention in the revised manuscript. Kim et al., 2010; Nature and related) 
. The authors should look into this (it shouldn't be too hard-the authors have already generated the data, they just need to further the analysis.)
As proposed by this referee, we have checked in the two parental cell lines, the levels of the upregulated proteins in hiPSCs vs. hESCs. These results are indeed interesting and are now discussed in the context of a possible residual "epigenetic memory" on page 11 and 12 in the revised version. We thank this referee for this valuable suggestion.
Moreover, it also quite conspicuous that the MS-based analysis found prominent pluripotency genes such as Zic3 and Utf1 that were differentially expressed between hiPSCs and hESCs. This should be commented on. We would like to suggest that for important genes that the MS analysis identified were differentially expressed between hiPSCs and hESCs (e.g. Utf1) that these findings could be validated by qPCR and/or Western Blot.
This reviewer is correct in pointing out that differences in expression of pluripotency genes could be especially relevant in this comparison. However, with the inclusion of a second hiPS cell line and the re-analysis of all the quantitative data, Zic3 and Utf1 were not found significantly regulated (Supplementary Table S2 and S3). Although UTF1 exhibited a slight enrichment in hESCs (also at the mRNA level), it has been recently reported that UTF1 gene expression displays marked differences across a panel of different hES cell lines (Bock et al. Cell 2011) which could explain our result.
The authors claimed that Dpp6 is differentially expressed between hiPSCs and hESCs (based on transcriptional analyses), but their proteome analysis did not find that Dpp6 was amongst the proteins differentially expressed between hiPSCs and hESCs (only Dpp7 was in the list). This is concerning in regards to their experimental design. Dpp6 in itself is pretty important if it is differentially expressed between hiPSCs and hESCs: it is involved in pancreatic cancer and ALS.
Indeed, DPP6 was found differentially expressed between hiPSCs and hESCs at the transcript level.
The presence of DPP7 in the original data set was due to issues related with protein groups. This has now been fixed with the re-analysis of all the data sets with Proteome Discoverer that takes protein groups into account for the protein inference. In the current MS data, we identified six members of the DPP family: DPP1, DPP2, DPP3, DPP4, DPP6 and DPP9. Unfortunately, DPP6 was identified by only one unique peptide which was not quantified. Nevertheless, all other DPP members were found highly enriched in the fibroblasts and only DPP4 showed significant changes between hESCs and 4Skin_iPS ( Figure 4A ).
The authors should see whether their MS-derived proteome of hESCs intersected with previously published proteomics data of ESCs (to add additional authenticity and confidence to their analysis.)
We have compared our data set with the largest proteomic analyses conducted to date on human pluripotent stem cells ( Remarkably, 90 % of the proteomes reported in these studies were identified in our study. This has now been mentioned in the text in page 6.
We are wondering if there are incongruities between proteome and transcriptome content. It seems like a straightforward thing to check, yet was apparently omitted-the authors just need to present a figure where they overlap their proteome and transcriptome contents and see if there are any significant differences. Do incongruities between proteome and transcriptome contents reflect an inherent weakness in the MS analysis, or rather, does it argue why transcriptome studies are not very useful predictors of proteome constitution?
In the first submission, we actually compared the results from both transcriptomics and proteomics approaches. The results derived from these comparisons were shown in Figure 2 (original version). Overall, we obtained a good correlation in the measured ratios. However, it seems that the outcome of such comparison was not easy to interpret. Therefore, in the revised version, we have created two new figures (Figure 4 and Supplementary Figure S11 ) that present the correlation of mRNA and protein levels in a more accessible manner. The inconsistencies found for some genes between both analyses (i.e. genes that did not show correlation) could be explained by several reasons. Linking proteomics and transcriptomics data is not trivial, mainly due to the different nature of both approaches and the lack of dedicated tools for the cross-comparison. We used a gene-centric approach based on the official HUGO gene symbols which implies that some proteins matched to multiple probes in the array (e.g. mapping splicing variants). Validation of these genes would require careful manual inspection of both transcriptomics and proteomics raw data which is not suitable in a high-throughput manner considering the depth of our analysis. Nevertheless, in sum, Munoz et al.'s report is still concise, timely, and provides useful resources for future study. It will be of interest to the iPS community, especially given the recent furor about the similarities (or lack thereof) between hESCs and hiPSCs. The concept of the manuscript and the results presented are very interesting-nevertheless, this study could be even further strengthened by a more detailed analysis of the data presented, and also a slight redirection in the focus of the paper to also examine more in depth the reportedly differentially expressed proteins between hESCs and hiPSCs. We believe that the manuscript may be accepted for publication with only minor revisions: namely, (1) accounting for minor grammatical/factual mistakes, as discussed below, (2) further analysis/discussion of differentially expressed proteins in hESCs vs. hiPSCs, and furthermore, (3) a brief consideration of whether their proteomics data presents any evidence for an "epigenetic memory" of hiPSCs' fibroblast origins. This sentence has been removed.
The claim that hiPSCs have the same faculty as hESCs for multilineage differentiation is incorrect and is antithetical to many reports (for example, see Hu et al., 2010; PNAS)
This sentence has been revised. The observed differences by Hu et al. during differentiation between hiPSCs and hESCs are now mentioned and referenced accordingly in the introduction.
"Several studies have directly compared hESCs and hiPSCs at the ... histone marks ... level"; also a bit awkward, maybe "...at the level of histone modifications" instead?
This sentence has been rewritten.
The title ("Human induced pluripotent stem cells and embryonic stem cells exhibit alike proteome signatures") is a bit awkward-especially, in regards to usage of the word "alike" and also "proteome" (it would flow better if it said "proteomic signatures").
The title has been changed. Guenther et al. (2010) in Cell Stem Cell, is unusual, given that this phrase has not been widely used before (whereas "gene expression programs" has been used) This has been corrected. Table  S3 ) and the claim should be toned down. The abstract has been re-written and the message of the paper, as suggested, has been toned down. The molecular characterization of hiPSCs with their bona fide hESCs is of paramount importance as significant differences could affect their potential use in clinical applications. We believe that our indepth MS-based analysis provides a complementary and important view of pluripotency, complementing mRNA and epigenetic data gathered by many groups on this issue in the last year. In the revised version, we have considerably extended our analysis including a second hiPS cell line and its parental foreskin fibroblasts. We have processed all the data using more stringent statistics and demonstrate now more statistically sound that hiPSCs and hESCs proteomes are nearly identical. Nevertheless, in both analyses, a small subset of proteins was found differentially expressed. The implications these differences could have in the context of the analysis are now discussed in the revised manuscript with special focus to a potential transcriptional/epigenetic memory from the precursor cells. We agree that some of our data may not have been covered comprehensively in the body of the text, possibly precluding appreciation of the depth of information provided. Consequently, we have extended our manuscript significantly and provided, where necessary, examples of the potential benefits of our proteome characterization. We believe that our analysis represents a definite confirmation for many of the previous screenings that were conducted mainly at the transcriptomic/epigenetic level. Therefore, we disagree that the high similarity found at the proteome level between hiPSCs and hESCs is anecdotal, especially considering previous reports that found a poor correlation between mRNA and proteins in differentiating mouse ESCs (Lu et al. Nature 2009). Although the proposed experiments by this reviewer could provide critical information on some studies that reported distinct differentiation potential between hiPSCs and hESCs (Hu et al. PNAS 2010), we believe this is out of the scope of our study. Nevertheless, we consider that our work might represent the starting point for the proposed analyses. Figure 1 that 
The abstract's usage of "protein expression programs", while evocative of

The abstract's claim that "...reprogramming completely extends to the expression level of the global hiPSCs proteome" seems to be a precocious conclusion (and has a minor grammatical error). This study did not find evidence that hiPSCs and hESCs were indistinguishable (see
In any case, it's clear to me via
.the median relative standard deviation (RSD) for these experiments was 30%). Please include this in the figure legend of Supplementary Figure 5 as well.
We have included the mean and the standard deviation for all the data sets in the legends of Supplementary Figure S6 , S7, S8 and S9.
Same for page 5, "...where more than half of the proteins were found to highly differentially expressed." Please state explicitly what fraction of proteins was found to be differentially expressed by what specific criteria. 2 fold differences?
This is now clarified in page 8 of the revised version.
On page 10, the authors describe surprisingly high ion target values for their experiments (10,000 for CID and 50,000 for ETD). Please supply the maximum allowed ion injection times for these experiments.
A clearer description of the MS methods used is provided in the Materials and Methods section.
On page 10, the authors search their data with up to 4 missed cleavages. I rarely find more than one missed cleavage to be believable. Is there a reason that this many missed cleavages were considered? Is a considerable portion of their data represented with more than 1 missed cleavage? It's a minor point, but does stand out as unusual.
The use of SCX as a pre-fractionation technique is based on the separation of peptides based on their charge state in solution. The refined SCX systems used in our analyses can separate nearly pure populations of singly charged peptides (containing mainly phosphorylated, N-terminally acetylated and C-termini peptides), doubly charged peptides (regular tryptic peptides), triply charged peptides (1 missed cleavage) and highly charged peptides (2 and more missed cleavages) (Gauci et al. Anal Chem 2009) and reviewed in (Mohammed et al. Curr Opin Biotechnol. 2011 ). In our analysis, each SCX fraction was searched in Mascot individually to find out the transitions between peptide populations and, accordingly, optimize the database searches. Using this approach, we found some SCX fractions enriched in 2 and 3 missed cleavages. However, in the revised version, we reanalyzed all the data sets allowing for a maximum of 2 missed cleavages. This is now explained in the Materials section.
In the submitted paper Munoz and co-authors quantify the proteomes of three different cell types: a hES cell line, a human somatic cell line (IMR90) and an induced pluripotent stem cell line derived from the IMR90 cells. In order to compare the three cell lines side-by-side the authors make use of dimethyl labeling in three isotopic variants, SCX fractionation and analyze the resulting peptide mixtures by LC-MS/MS using both CID and ETD for peptide sequencing. This manuscript mainly presents two key contributions: 1) The difference in protein abundances between iPS cells and the somatic cell line that they are derived from is really significant. 2) There are very few differences in protein expression levels between the embryonic stem cell line and the iPS cells. But although this paper is potentially interesting there are a number of shortcomings in the current version that needs to be addressed: -The paper is not very exciting in its current form. I lack some novel biological findings. It is not surprising that the proteome between the iPS cells and the somatic cell line is different, but what does the observed differences mean (in a biological and cellular context)?
We agree with this reviewer that the manuscript might be relatively short in its original form. Encouraged by the positive comments from the reviewers, we extended our analysis to a second hiPS cell line. In the revised version, we have re-analyzed all our data sets, adding experimental evidence that confirmed the earlier findings, revised all the figures and tables and provided explanation where necessary. Consequently, we have formatted a large part of the manuscript which has increased in length notably. In addition, the biological relevance of the observed differences in the context of hiPSCs and hESCs characterization studies is discussed thoroughly.
-What type of proteins are stem cell specific and which proteins are specific to the somatic cells? There must be some interesting biology hidden in the data. The authors should attempt to do some more advanced bioinformatic analyses to extract biological insight from their dataset. For example, the proteins that are significantly more abundant in the iPS cells are they enriched for known transcriptional targets of Nanog, Sox2 and Oct4?
As suggested by this referee, we have now highlighted, in the main text, the differences between the hiPSCs and their somatic precursor cell lines in a separate sub-heading entitled "Profound differences in the proteomes of hiPSCs and their parental fibroblasts cell lines" (Page 7-8). The results derived from these comparisons were analyzed with bioinformatics tools such as String (Snel et al. NAR 2000) which revealed highly interconnected protein networks in both the somatic and hiPS cell lines ( Figure 5 ). In addition, we also examined the intersection of our data set with the genome-scale location (chromatin immunoprecipitation coupled with microarrays read-out) published by (Boyer et al. Cell 2005) for SOX2. NANOG and OCT4 target genes. This is discussed now in page 12 of the revised version.
-The authors should also compare their differentially regulated proteins (between the iPS cells and the somatic cell lines) with other large-scale proteome quantification datasets previously published on stem cell differentiation, for example: O'Brien et al, Mol Cell Proteomics 2010, as well as Rigbolt et al, Science Signaling 2011.
We have carefully considered this suggestion and went through both papers and found that both excellent data sets may not be appropriate for comparison with our results. Firstly, the OíBrien analysis was performed on mouse (not human) P19 (embryonic cancer cells) and 129SvEv (mouse embryonic stem cells) which were induced to neural differentiation (not fibroblasts). On the other hand, for the second paper by Rigbolt et al, although human embryonic stem cells were used, they were induced to undergo non-directed differentiation. Besides, while they measured the dynamic changes in the proteome and phosphoproteome during the ongoing process of differentiation, our study caters more for the proteomic comparison of 2 end-points, i. 
I also have some questions and concerns about the MS analysis/computational parts of the manuscript: -The authors need to be more rigorous in their data analysis. They claim that they have identified 10,608 proteins -but looking through the supplementary data it is clear that this is a significant over-estimation of the actual number of proteins: First of all, the dataset is only FDR filtered at the peptide level, this is not acceptable for a proteome analysis.
The parameters used to filter the data are explained in the Materials and Methods section. In the revised version, we have used more stringent criteria (i.e. Mascot Ion Score >20) which resulted in an even smaller FDR at the peptide level. Based on these results, we roughly estimated the protein FDR of all the four MS analyses which ranged between 2.5 and 5%. Details concerning the MS analysis are provided in Supplementary Table S1 .
Secondly, in the current protein list more than 40% of proteins are identified by a single peptide (a so-called one hit wonder)! This is significantly higher than for any other large-scale dataset published to date.
All the data sets have been re-analyzed with Proteome Discoverer (Thermo). The evaluation of protein identification is presented in Supplementary Figure S2 and S3 for the IMR90 and 4Skin data sets respectively. We observed a good correlation in the two biological replicas conducted in each experiment for several parameters including the number of PSMs/protein and sequence coverage. Therefore, we combined the data sets from both replicas and plotted the distributions of unique peptides/protein and sequence coverage/protein which showed that more than 90% of the reported proteins were identified on the basis of at least two unique peptides. Based on these results, we believe our data set outperforms several of the published data sets in large-scale proteomic analyses.
Thirdly, 30% of proteins are not quantified!? -This is an unacceptable high number of peptide identifications that cannot be quantified.
As mentioned earlier, all the data sets have been re-analyzed using unattended protein quantification (Proteome Discoverer). The number of quantified and identified proteins is reported in Supplementary Table S1 for all the four MS analyses conducted. Overall, we were able now to quantify around 85% of the identified proteins.
-Likewise, it is not clear how good the identification rates and quantitation accuracy between replicates are? How many proteins were reproducibly quantified between the biological replicates? And what kind of standard deviations on the protein and peptide ratios were observed between replicates?
The analysis of technical and biological variability it is now clearly described in two new figures (Supplementary Figure S4 and Thank you again for submitting your work to Molecular Systems Biology. We have now heard back from the two referees who agreed to evaluate your manuscript. As you will see from the reports below, the referees were substantially divided in their opinion of this work. The first reviewer is now largely supportive, but the second reviewer raised a series of fundamental concerns. These concerns remain substantial enough that, I am afraid to say, they must preclude publication of this work in its present form.
The second reviewer felt that serious issues with the statistical analysis methods used here raised important doubts about the main biological conclusions reached in this work. Most importantly, this reviewer felt that the question of how similar these proteomes profiles were to each other had not been addressed in a statistically rigorous manner. S/he felt that the stringent 3-fold cutoff employed was rather arbitrary and potentially overly-stringent, which could create the somewhat misleading impressive that there are very few reproducible changes between the iPS and ESC proteomes. Along these lines, the editor notes that this stringent threshold could potentially underpower functional enrichment analyses, i.e. real functional shifts may be missed. For these reasons, and because of a series of additional concerns regarding the presentation of the statistical methods, the second reviewer was fundamentally unconvinced that the claim "hESCs and hiPSCS exhibit nearly identical proteomes" is correct, and felt that the data may indicate otherwise.
Nonetheless, after looking closely at this data, I think it is clear that the hiPSCs are *much* more similar to the hESCs than their parent fibroblast lines, and lack the broad order-of-magnitude protein expression shifts seen in the iPS-fibroblast comparisons. It remains possible that a combination of rewording, clarification, and additional, rigorous statistical analysis, *may* make this work appropriate for publication in Molecular Systems Biology. Please note, in general MSB only allows one round of major revision. But, given the positive response from the first reviewer, and since the issues raised by the second reviewer may be addressable with additional statistical analysis, we would like to encourage you to submit a final revision of this work. Any such revision would need to convincingly and thoroughly address the following points:
--Proteins that are differentially expressed between the datasets need to be identified within a rigorous statistical framework. The current analysis repeatedly describes proteins as "significantly regulated" but the analysis relies on an arbitrary and stringent fold-change cutoff, and does not provide explicit estimates of statistical significance. Any new analysis should report estimates of both the false positive rate, and ideally, the false negative rate (i.e. estimate how many truly differentially expressed genes are likely to be missed by the analysis). A basic component of this analysis should be a rigorous analysis of whether the amount of differential protein expression between hiPSC and hESC exceeds what would be expected from a null distribution (given the variance observed in the biological replicates). This analysis should put on a more solid, quantitative footing the question of how similar these datasets really are. Claims in the manuscript should then be revised to avoid qualitative statements that are not directly supported by the data, e.g. "nearly identical".
--While the functional analysis of the differentially expressed genes did not reveal a clear fibroblast signature remaining in the hiPSC cells, GO analysis may miss more subtle patterns. As suggested by the first reviewer, it would be important to directly test whether those proteins that are differentially expressed between hiPSC and hESC cells tend to move hiPSC protein expression toward the fibroblast expression levels (i.e. directly test whether there is a residual fibroblast-like expression bias). This should be testable using the existing data, combined with some additional statistical testing. Naturally, a positive result, while interesting, would require further revision of the claims regarding the near identity of the hiPSC and hESC proteomes.
--Lastly, the statistical analysis needs to be described, throughout, in more detail, and the issues raised by the second reviewer need to be convincingly clarified.
If you feel you can satisfactorily deal with these points and those listed by the referees, you may wish to submit a revised version of your manuscript. Please attach a covering letter giving details of the way in which you have handled each of the points raised by the referees. As you probably understand that we can give you no guarantee at this stage that any revised work will be acceptable for publication. We will make every effort to evaluate any revised in an expedited fashion, although, we may send any revised work back to the second reviewer for comment if you feel this is necessary.
*PLEASE NOTE* As part of the EMBO Publications transparent editorial process initiative (see http://www.nature.com/msb/journal/v6/n1/full/msb201072.html), Molecular Systems Biology now publishes online a Review Process File with each accepted manuscript. Please be aware that in the event of acceptance, your cover letter/point-by-point document will be included as part of this file, which will be available to the scientific community. Authors may opt out of the transparent process at any stage prior to publication (contact us at msb@embo.org). More information about this initiative is available in our Instructions to Authors.
Yours sincerely,
Editor -Molecular Systems Biology msb@embo.org ----------------------------------------------------------------------------referee reports:
Reviewer #1 (Remarks to the Author):
The authors have done an admirable job to address this reviewer's concerns. In response to our previous concern of small sample size (1 hESC line vs. 1 hiPSC line), the authors have now compared two hiPSC lines (one derived from the IMR90 fibroblast line and another derived from foreskin fibroblasts) to their fibroblast antecedents in addition to the one hESC line. The authors reify at the protein level the results of numerous previous studies that suggest pervasive transcriptional similarities between hESCs and hiPSCs (e.g., Guenther et al., 2010; Cell Stem Cell) but have made an important revision in the focus of their manuscript to look at consistent protein differences between hESCs and hiPSCs, as we have suggested. It appears that both foreskin-derived and IMR90-derived hiPSCs consistently express higher levels of two proteins (Cdh2 and Uhrf1) than hESCs, and that these two hiPSC lines consistently express lower levels of two proteins (B2M and Plp2) than hESCs. It is conceivable that there are additional consistently hiPSC-upregulated or hiPSC-downregulated proteins but that there were not recovered due to the nature of the MS approach or technical issues. Nevertheless, these results pique this referee's interest.
It would be interesting to see whether fibroblasts express high levels of Cdh2 and Uhrf1 to start out with and whether this makes the resultant reprogrammed hiPSCs express higher levels of these proteins. Should this be the case, this thence would make a case for fibroblast-derived hiPSCs having an "epigenetic memory" of their fibroblast origins; but this is not yet clear from the data.
The authors should also be credited for a significant improvement in the presentation of their data with the introduction of Fig. 4 , which provides a nice illustrative comparison of the microarray vs. MS data for some select genes. However, it might be nice if the authors moved a more global comparison of the microarray vs. MS data from the supplementary figures to a main text figure (as per their original submission, but with an easier-to-understand figure.)
Just a quick comment regarding the new Fig. 3 , which in our candid opinion appears slightly unnecessary; its general import seems to be that proteins in each cell line interact with one another, which seems somewhat superfluous. Moreover, are the STRING connections statistically significant? (No mention was made in the main text.) There are also a few sentences throughout the manuscript that are biologically ambiguous (e.g., "This allows the assignment of hiPSCs to "pluripotent grades" on the basis of quantitative measurements").
Nevertheless, the manuscript in its entirety has been significantly improved. The manuscript may be accepted for publication as is, or with extremely minor revisions to the text and figures. The authors' results regarding proteomic similarities and divergences between hESCs and hiPSCs complement previous transcriptional and epigenetic analyses of these cell types and should divulge very useful resources for study to the reprogramming community.
Here, Munoz et al. present a revised manuscript that includes the analysis of a second iPSC cell line as additional evidence of their claim that ESCs and iPSCs "exhibit nearly identical proteomes".
Unfortunately, many of my original primary concerns and suggestions were either ignored completely or poorly addressed, and I remain unconvinced that the authors present in this revised manuscript an analytically, statistically, and biologically convincing case for this assertion.
The authors have failed to convince me that their study does anything but further muddy the waters regarding the relative similarity or differences between ESCs and iPSCs. In the absence of a rigorous statistical framework, they use phrases such as "nearly identical", "very high degree of similarity", "almost identical levels", etc. to wave their hands regarding the quantification results they have in front of them. In a shocking juxtaposition of opposing logic, they use the "stringent criterion" of 3-fold difference in expression to define the boundaries of "similarity", and then note that "98.3% and 99.5% of the proteins showed similar levels [between ESCs and iPSCs] in Experiment 1 and 2 respectively". Where does the seemingly arbitrary 3-fold cutoff for "similarity" come from, anyway? Is it defined by the data itself, or taken out of thin air? Is a 2-fold difference in protein expression "similar"? We should review the literature on Myc protein function to remind ourselves of the downstream effects that 1.5 -2-fold differences in a single transcription factor protein expression can have on literally thousands of target genes.
Indeed, the addition of the second dataset (4Skin) makes me even more nervous regarding these points. In contrast to the authors, I believe strongly that the 4Skin dataset contains sufficient power to allow for differences of less than 3-fold to be statistically significant. Just look at Supplementary Figure S5 -D -there are clearly biologically reproducible differences in that replicate experiment at a cutoff of less than 3-fold. A Pearson coefficient of 0.56 in a correlation plot of a purported null distribution is stunning! While this is a great figure, it does more to support this idea that there are potentially many, albeit very subtle, differences in protein expression between ESCs and iPSCs than to prove that they are nearly identical.
There are a number of concerns regarding the presentation of data in this study. First, the authors are not straightforward in how they present their data, which is unsettling. For example: in the abstract, the authors "present a quantitative mass spectrometry-based analysis of hESCs, two different hiPSCs and their precursor fibroblast cell lines to a cumulative depth of 10,628 proteins". This is misleading, because nowhere in the study do the authors actually quantify 10,628 proteins. Although they claim to identify 10,628 proteins in the union of all datasets (including biological replicates), the number of quantified proteins is significantly less than that. Later in the text, they note that 5835/3537 and 7154/4718 proteins were quantified in the union/intersection of biological replicates for the IMR90 and 4Skin experiments, respectively. But nowhere in the text do they state explicitly that 2,592 proteins were quantified in the intersection of the two experiments (IMR90 and 4Skin) -I had to parse this out of the Supplementary Data tables myself. This is unfortunate and unnecessary, because very few of the proteins that are identified but not quantified are used for any real purpose in the study.
Although this may seem like a minor point, it is indicative of the lack of consistency in the data analysis in general in this study. The authors use quantification data only for those proteins identified in the intersection of biological replicates, but use qualitative identification numbers from the union of all datasets together. Why? I would advocate for the use of protein identification and quantification results found in the intersection of the datasets.
There are other concerns regarding the data itself. First, there is no peptide identification or quantification data presented here. This should be supplied as an additional supplementary table. In addition, there are some errors/inconsistencies/oddities in the data as supplied:
1. The data in Supplementary Table 2 for biological replicate #2 is supplied as the "Medium/Light" ratio and not the "Medium/Light log2" ratio. This causes confusion in re-creating information contained elsewhere in the study (e.g. Supplementary Table 4 ). This should be fixed.
2. Why aren't all of the proteins expressed at 3-fold difference listed in Supplementary Table 4 and discussed in the text? On page 7, the authors indicate that 17 and 79 proteins are differentially regulated in IMR90 and 4Skin experiments, and these proteins are listed in Supp. Table 4 . However, when one looks at the primary data in Supplementary Tables 2 and 3 , there are many proteins represented here that are quantified in both replicates at > 3-fold differences, but missing from the final list. I find 58 total proteins with > 3-fold differences that are quantified in both replicates in the IMR90 dataset, and 138 total proteins that are quantified in both biological replicates in the 4Skin dataset and > 3-fold different (</> 1.58 log2 ratio). A few of these are contaminants, but most are not. For example, the protein OXCT1 (IPI00026516.1) was quantified with an average ESC/iPSC ratio of -2.09 (log2) in the IMR90 dataset, but it is missing from the final count in Supplementary  Table 4 . In addition, IFIT5 (IPI00012756.1) was quantified with an average ESC/iPSC ratio of 2.29 (log2) in the FSkin dataset, but is also not in the final count.
Note that in several cases, some proteins are up in ESCs in one cell line, but down in ESCs in another, and vice-versa. Note also that there are an additional 60 proteins in the FSkin dataset that are > 3-fold regulated in that cell line, and are also quantified in the IMR90 dataset that are not shown here.
My guess to the answers here is that the authors first intentionally selected only those proteins that were quantified as > 3-fold in EACH biological replicate (instead of using the average). Then, using only this pre-filtered list, made the comparisons listed on page 7. When attempting to be "stringent" in defining only those features that are most convincingly "different" between two samples, this seems conservative and therefore appropriate. But the authors then turn around and use this stringency to establish that the cell lines are nearly identical -and this claim is, in my view, false.
It is for these reasons that I feel I cannot support the publication of this study as it stands -I cannot support the authors' claim that the ESCs and iPSCs used in this study are "nearly identical". In my own view of the data, there are many significant, albeit in most cases minor, differences between in protein abundance between them that may also be biologically relevant. We appreciate the highly positive comments from this referee, especially concerning the big effort done on our side to generate a second data set that we believe has substantially improved our work. We agree with this reviewer that there might be additional and consistent differences between hiPSCs and hESCs. Following the comments from Reviewer #2, we have now applied statistical analysis in our data sets (i.e. Significance Analysis of Microarrays) which showed 58 genes to be significantly differentially expressed between hiPSCs and hESCs.
It would be interesting to see whether fibroblasts express high levels of Cdh2 and Uhrf1 to start out with and whether this makes the resultant reprogrammed hiPSCs express higher levels of these proteins. Should this be the case, this thence would make a case for fibroblast-derived hiPSCs having an "epigenetic memory" of their fibroblast origins; but this is not yet clear from the data.
We are aware that the presence of an epigenetic memory from the parental cell lines could explain certain residual differences between hiPSCs and hESCs. We have now investigated this possibility for all the 12 statistically significant proteins (hiPSCs>hESCs) and found that only 1 of them (TFRC) exhibited a higher level in both the parental fibroblasts cell lines. This has now been incorporated in the Discussion section on page 11.
The authors should also be credited for a significant improvement in the presentation of their data with the introduction of Fig. 4 (as per their original submission, but with an easier-to-understand figure.) We thank this referee for his positive comments with regards to the new figures. Figure 4 was originally intended to show the mRNA levels of the significantly regulated proteins (as measured by parallel gene expression profile analyses). Therefore, we believe that a global comparison of mRNA and proteins levels may be out of the scope of this study and distract from the main message.
Instead, in the current version, we have created a newer version of Figure 4 including all the new significantly regulated proteins between hESCs/hiPSCs and Fibroblasts/hiPSCs as well. In the hESCs/hiPSCs comparison, error bars have been added to illustrate the precision of both proteomic and transcriptomic measurements. Fig. 3 Figure 3 has now been moved to the Supplementary material ( Figure S12 in the current manuscript). A new Figure 3 has been created that shows the log2 ratios, in the form of heat maps, of the 2,638 proteins that were quantified in all the four experiments. The significantly regulated proteins (SAM) found between hESCs/hiPSCs and Fibroblasts/hiPSCs are also shown in the new Figure 3 .
Just a quick comment regarding the new
There are also a few sentences throughout the manuscript that are biologically ambiguous (e.g., " This allows the assignment of hiPSCs to "pluripotent grades" on the basis of quantitative measurements").
This sentence has been removed in the current revised version. We agree that some of the terms used in the manuscript (e.g. nearly identical) could not be fully supported by the data in the absence of statistical analysis. We also agree that fold-change lower than our original threshold of 3 could have an important biological impact. However, the use of a 3-fold change as a threshold was dictated partially by the data itself and the applied experimental design constraints. The measured variation in a quantitative experiment determines the statistical power of the analysis. In Levin et al. 2011, a simulation is conducted to determine the theoretical cut-offs that can be used in quantitative analyses as a function of the sample size. For instance, in order to measure a 2-fold change in an experiment in which the variation is 50% (technical and biological variation), the minimum number of biological replicas required for the analysis to be powered would be ~ 5 (power set to 0.8 and confidence level to 0.05). An experimental design that includes this number of biological replicas is not feasible considering the proteome depth achieved in our analysis (on average, 87 LC-MS/MS runs were performed per experiment). Therefore, it seems appropriate to use a strict cut-off of 3-fold considering that the variability measured in our data was close to 46% (median). Nonetheless, and following the recommendations of this referee, we have now processed all our datasets with a statistical frame named Significance Analysis of Microarrays (SAM) (Tusher et al. 2001) . We note that other statistical approaches are available, but we did chose for SAM as it has been successfully applied to proteomic experiments (Roxas & Li, 2008) and one of its main features is the estimation of false discovery rates for a defined set of significant values. Using SAM on the 2,638 proteins that were quantified in all the four experiments, we have found 58 proteins significantly regulated between the two hiPS cell lines and the hESCs (FDR=1.27%): 46 proteins hESCs>hiPSCs and 12 proteins hESCs<hiPSCs. The new list of significantly regulated proteins is presented now in Supplementary Table S4 and in Figure 3 of the manuscript. These 58 proteins only represent 2.16% of the quantified proteomes and clearly confirm the high similarity of hESCs and hiPSCs described by other groups using genomic approaches. On the other side, profound differences were found (using SAM) between the hiPSCs and their parental fibroblasts in which 73.4% (FDR=1.1%) of the proteins were found significantly changing. The description of the statistical method used can be found in a new sub-heading in the Materials section. We believe that the statistical analysis of our data provides now solid, quantitative and unbiased evidence that supports the high similarity of hESCs and hiPSCs at the proteome level. We therefore thank this reviewer for the comment. We apologize if this referee did not find adequate the way we presented our results. We agree that the following sentence in the abstract: "present a quantitative mass spectrometry-based analysis of hESCs, two different hiPSCs and their precursor fibroblast cell lines to a cumulative depth of 10,628 proteins" can be misleading as quantitative data was in fact not obtained for all these proteins. Consequently, we have now removed this sentence from the abstract. In addition, we have now added, in page 6, the number of proteins present at the intersection of all four experiments in terms of identification (3,001) and quantification (2,683). We are sorry for the problem this might have caused to this referee during the revision process. However, we do not agree about the suggested lack of consistency of our data in the form it was presented. The primary reason we provide two sets of numbers (identification and quantification) is to allow the reader to assess data quality, a recommendation by the general proteomics community (Bantscheff et al. Anal Bioanal Chem 2007) . Accordingly, the identifications were presented in our study as cumulative numbers whereas quantification values were restricted to the intersection of the different data sets. Table 2 for biological replicate #2 is supplied as the "Medium/Light" ratio and not the "Medium/Light log2" ratio. This causes confusion in re-creating information contained elsewhere in the study (e.g. Supplementary Table 4 ). This should be fixed. This has been now corrected. We apologize for the inconvenience. In the previous version of the manuscript, the arbitrary criterion used to define differentially expressed proteins was ± 3-fold (1.58 in log2) consistently in each biological replica. This was clearly stated twice in pages 7 and 8 in the previous version. We have now re-examined Supplementary Tables S2 and S3 and did not find inconsistencies with the final list (Table S4 ). For instance, OXCT1 (IPI00026516.1) was only included as a differentially expressed protein in the 4Skin data set because in the IMR90 data set-Biological Replica 1, the log2 ratio was -1.321 and therefore did not pass the above mentioned criteria. A similar situation was found for the other example, IFIT5 (IPI00012756.1), in which a ratio of -0.398 was found in Biological Replica 1 (4Skin data set) and, consequently, was not included in our final list. We only found two proteins that showed consistent ratios above/below the defined threshold (i.e. UTF1 and NT5E) and did not appear in our final list Table S4 . That was due to the fact that these two proteins had a missing channel and were therefore rejected. We apologize for this misunderstanding. As explained above, indeed, we only selected those proteins quantified ±1.58 (3-fold) consistently in each biological replica. This criterion was indicated in page 7 and 8 of the previous version of the manuscript. The rationale behind this criterion was to make sure we only selected those proteins with reproducible measurements. The average ratio is very sensitive to the presence of outliers (i.e. one extreme ratio in one of the replicas). Although the median represents a more robust measurement of a distribution, it was not suitable in our study because only two replicas were performed per experiment (if N=2, average and median have the same values).
Why aren't all of the proteins expressed at 3-fold difference listed in Supplementary
It is for these reasons that I feel I cannot support the publication of this study as it stands -I cannot support the authors' claim that the ESCs and iPSCs used in this study are "nearly identical". In my own view of the data, there are many significant, albeit in most cases minor, differences between in protein abundance between them that may also be biologically relevant.
We have now re-analyzed all our data sets using rigorous statistical analysis which has shown, indeed, a higher number, when compared to the static 3-fold cutoff used before, of differences between hiPSCs and hESCs. However, the 58 proteins found significantly regulated only represent a minor fraction of their proteomes (2.2%) and consequently confirmed our previous findings regarding the high similarity of hESC and hiPSCs in which 97.8% of the proteins remained unchanged.
Acceptance letter 04 October 2011
Thank you again for sending us your revised manuscript. We are now satisfied with the modifications made and I am pleased to inform you that your paper has been accepted for publication.
Before we send this work to production we would like to give you the opportunity to make small revisions to the text as you see necessary. The editor does note that the phrase on page 17 "to find out significantly regulated proteins" would probably be better written as "to identify significantly regulated proteins". You may also wish to consider citing the related work by Phanstiel et al. (2011) that was recently published in Nature Methods. A new manuscript document with any changes can be sent to us as an attachment to a reply email, ideally within the next few days.
Thank you very much for submitting your work to Molecular Systems Biology.
Sincerely, Editor -Molecular Systems Biology msb@embo.org
The study by Munoz et al. has improved after a second revision. Included in this version of the manuscript is a SAM-based analysis of significance for differences between the datasets. While this is still somewhat weak, and poorly described in the Methods section, it does represent a more unbiased approach and is considered an improvement over an arbitrary cutoff. Ultimately, it will be for the stem cell biological community to decide for themselves how to interpret these results.
There are no significant additional considerations.
